These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6688407)

  • 1. Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses.
    von Schrader HW; Buscher G; Dierdorf D; Mügge H; Wolf D
    Int J Clin Pharmacol Ther Toxicol; 1983 Jun; 21(6):311-21. PubMed ID: 6688407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of the clinical pharmacokinetics of nabumetone.
    Hyneck ML
    J Rheumatol Suppl; 1992 Nov; 36():20-4. PubMed ID: 1474531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nabumetone--a novel anti-inflammatory drug: bioavailability after different dosage regimens.
    von Schrader HW; Buscher G; Dierdorf D; Mügge H; Wolf D
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):672-6. PubMed ID: 6526543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses.
    Soma LR; Uboh CE; Rudy JA; Smith MS
    Am J Vet Res; 1996 Apr; 57(4):517-21. PubMed ID: 8712517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penetration of nabumetone into inflammatory exudates in the rat.
    Haddock RE; Jeffery DJ; Mangan FR; Pardon IS
    J Pharm Pharmacol; 1983 Jun; 35(6):358-62. PubMed ID: 6135773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver insufficiency as a factor modifying the pharmacokinetic characteristic of the preparation nabumetone.
    Maleev A; Vlahov V; Gruev I; Dierdorf D; Kostova N; Bacracheva N
    Int J Clin Pharmacol Ther Toxicol; 1986 Aug; 24(8):425-9. PubMed ID: 3759278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6MNA (6-methoxy-2-naphthylacetic acid): comparison with indomethacin.
    Melarange R; Gentry C; O'Connell C; Blower PR; Neil C; Kelvin AS; Toseland CD
    Agents Actions; 1992; Spec No():C82-3. PubMed ID: 1442340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism of nabumetone (BRL 14777) by various species including man.
    Haddock RE; Jeffery DJ; Lloyd JA; Thawley AR
    Xenobiotica; 1984 Apr; 14(4):327-37. PubMed ID: 6464502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of food and various antacids on the absorption of tenoxicam.
    Day RO; Lam S; Paull P; Wade D
    Br J Clin Pharmacol; 1987 Sep; 24(3):323-8. PubMed ID: 3499163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [6-methoxy-2-naphthylacetic acid level in plasma, synovial fluid and adjacent tissue in patients with rheumatoid arthritis or gonarthroses after a 4-day therapy with nabumetone (Arthaxan)].
    Miehlke RK; Schneider S; Sörgel F; Muth P; Henschke F; Fedder M
    Z Rheumatol; 1991; 50(2):103-8. PubMed ID: 1872041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of antacid and aspirin on the bioavailability of isofezolac in man.
    Rocher I; Henry JF; Flouvat B
    Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):464-9. PubMed ID: 6500763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of antacid and food on the absorption of proquazone (Biarison) in man.
    Ohnhaus EE
    Int J Clin Pharmacol Ther Toxicol; 1980 Mar; 18(3):136-9. PubMed ID: 7380586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers.
    Grunder G; Zysset-Aschmann Y; Vollenweider F; Maier T; Krähenbühl S; Drewe J
    Antimicrob Agents Chemother; 2006 Jan; 50(1):68-72. PubMed ID: 16377669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology.
    Mangan FR; Flack JD; Jackson D
    Am J Med; 1987 Oct; 83(4B):6-10. PubMed ID: 3688000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extractionless determination of 6-methoxy-2-naphthylacetic acid, a major metabolite of nabumetone, in human plasma by high-performance liquid chromatography.
    de Jager AD; Hundt HK; Hundt AF; Swart KJ; Knight M; Roberts J
    J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):247-51. PubMed ID: 10821411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.
    Kubitza D; Becka M; Zuehlsdorf M; Mueck W
    J Clin Pharmacol; 2006 May; 46(5):549-58. PubMed ID: 16638738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
    Stampfuss J; Kubitza D; Becka M; Mueck W
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of antacid on the bioavailabiity of lithium carbonate.
    Goode DL; Newton DW; Ueda CT; Wilson JE; Wulf BG; Kafonek D
    Clin Pharm; 1984; 3(3):284-7. PubMed ID: 6428800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition?
    Davies NM
    Clin Pharmacokinet; 1997 Dec; 33(6):404-16. PubMed ID: 9435990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies.
    Smit JW; Oh C; Rengelshausen J; Terlinden R; Ravenstijn PG; Wang SS; Upmalis D; Mangold B
    Pharmacotherapy; 2010 Jan; 30(1):25-34. PubMed ID: 20030470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.